Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IDYA IDEAYA Biosciences	$21.67 -0.9%	$19.56	$13.45 ▼ $44.42	$1.90B	0.05	1.03 million shs	780,090 shs
IRWD Ironwood Pharmaceuticals	$0.70 +0.4%	$0.71	$0.53 ▼ $7.11	$113.53M	0.24	2.57 million shs	3.80 million shs
RYTM Rhythm Pharmaceuticals	$61.99 +0.8%	$62.34	$39.46 ▼ $69.89	$3.94B	2.3	551,150 shs	719,497 shs
VKTX Viking Therapeutics	$26.01 -1.0%	$26.90	$18.92 ▼ $81.73	$2.92B	0.65	4.04 million shs	2.95 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IDYA IDEAYA Biosciences	0.00%	-2.30%	+15.14%	+16.57%	-41.42%
IRWD Ironwood Pharmaceuticals	0.00%	+13.16%	+23.89%	-52.91%	-88.48%
RYTM Rhythm Pharmaceuticals	0.00%	-1.45%	-0.59%	+15.39%	+48.05%
VKTX Viking Therapeutics	0.00%	-0.27%	-3.60%	-11.17%	-50.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IDYA IDEAYA Biosciences	3.5955 of 5 stars	3.5	2.0	4.4	1.4	1.7	0.0
IRWD Ironwood Pharmaceuticals	4.3469 of 5 stars	4.1	3.0	3.4	1.1	0.8	1.9
RYTM Rhythm Pharmaceuticals	4.077 of 5 stars	3.5	3.0	4.3	2.7	0.8	0.6
VKTX Viking Therapeutics	4.4289 of 5 stars	4.5	1.0	4.7	2.3	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IDYA IDEAYA Biosciences	2.93	Moderate Buy	$54.27	150.45% Upside
IRWD Ironwood Pharmaceuticals	2.13	Hold	$4.78	581.77% Upside
RYTM Rhythm Pharmaceuticals	3.00	Buy	$76.62	23.59% Upside
VKTX Viking Therapeutics	3.00	Buy	$87.15	235.08% Upside

Current Analyst Ratings Breakdown

Latest RYTM, VKTX, IDYA, and IRWD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	RYTM Rhythm Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $94.00
5/22/2025	IDYA IDEAYA Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$63.00 ➝ $66.00
5/7/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$66.00 ➝ $72.00
4/29/2025	VKTX Viking Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	VKTX Viking Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$104.00
4/28/2025	VKTX Viking Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$95.00 ➝ $75.00
4/24/2025	VKTX Viking Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$105.00 ➝ $102.00
4/24/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00 ➝ $102.00
4/17/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00 ➝ $102.00
4/16/2025	IRWD Ironwood Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/15/2025	IRWD Ironwood Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$7.00 ➝ $1.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IDYA IDEAYA Biosciences	$7M	271.12	N/A	N/A	$12.25 per share	1.77
IRWD Ironwood Pharmaceuticals	$351.41M	0.32	$0.05 per share	14.19	($1.88) per share	-0.37
RYTM Rhythm Pharmaceuticals	$130.13M	30.31	N/A	N/A	$0.35 per share	177.11
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$7.90 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IDYA IDEAYA Biosciences	-$274.48M	-$3.59	N/A	N/A	N/A	N/A	-29.28%	-27.68%	8/5/2025 (Estimated)
IRWD Ironwood Pharmaceuticals	$880K	-$0.20	N/A	2.81	N/A	-9.89%	-1.87%	-3.93%	8/6/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$260.60M	-$2.81	N/A	N/A	N/A	-123.26%	-739.62%	-44.27%	8/5/2025 (Estimated)
VKTX Viking Therapeutics	-$109.96M	-$1.15	N/A	N/A	N/A	N/A	-14.41%	-14.02%	7/23/2025 (Estimated)

Latest RYTM, VKTX, IDYA, and IRWD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	IRWD Ironwood Pharmaceuticals	-$0.05	-$0.14	-$0.09	-$0.23	$67.02 million	$41.14 million
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million
5/6/2025	Q1 2025	IDYA IDEAYA Biosciences	-$0.75	-$0.82	-$0.07	-$0.82	$2.10 million	N/A
4/23/2025	Q1 2025	VKTX Viking Therapeutics	-$0.31	-$0.41	-$0.10	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IDYA IDEAYA Biosciences	N/A	13.92	13.92
IRWD Ironwood Pharmaceuticals	N/A	3.34	3.34
RYTM Rhythm Pharmaceuticals	N/A	3.30	3.13
VKTX Viking Therapeutics	N/A	44.25	44.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IDYA IDEAYA Biosciences	98.29%
IRWD Ironwood Pharmaceuticals	N/A
RYTM Rhythm Pharmaceuticals	N/A
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
IDYA IDEAYA Biosciences	2.50%
IRWD Ironwood Pharmaceuticals	12.70%
RYTM Rhythm Pharmaceuticals	6.10%
VKTX Viking Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IDYA IDEAYA Biosciences	80	87.58 million	85.39 million	Optionable
IRWD Ironwood Pharmaceuticals	220	161.82 million	141.27 million	Optionable
RYTM Rhythm Pharmaceuticals	140	63.62 million	59.74 million	Optionable
VKTX Viking Therapeutics	20	112.31 million	107.71 million	Optionable

RYTM, VKTX, IDYA, and IRWD Headlines

Recent News About These Companies

2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts

June 21 at 6:10 PM | fool.com

Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know

June 20 at 8:51 PM | msn.com

Institute for Wealth Management LLC. Purchases 9,735 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 19, 2025 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Acquired by GAMMA Investing LLC

June 19, 2025 | marketbeat.com

MN Wealth Advisors LLC Has $450,000 Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 18, 2025 | marketbeat.com

Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet

June 16, 2025 | zacks.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Sold by Handelsbanken Fonder AB

June 16, 2025 | marketbeat.com

Viking Therapeutics (NASDAQ:VKTX) Shares Down 5.7% - Should You Sell?

June 13, 2025 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Holdings Lifted by Compagnie Lombard Odier SCmA

June 13, 2025 | marketbeat.com

Viking Therapeutics (VKTX) Rises on Expected Developments

June 12, 2025 | insidermonkey.com

Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note

June 12, 2025 | zacks.com

We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely

June 12, 2025 | finance.yahoo.com

Harbor Capital Advisors Inc. Sells 14,094 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 12, 2025 | marketbeat.com

Analysts Issue Forecasts for VKTX FY2026 Earnings

June 11, 2025 | marketbeat.com

Wesbanco Bank Inc. Purchases 12,000 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 11, 2025 | marketbeat.com

Viking Therapeutics Target of Unusually Large Options Trading (NASDAQ:VKTX)

June 10, 2025 | marketbeat.com

Viking Therapeutics (NASDAQ:VKTX) Trading Up 7.1% - Still a Buy?

June 10, 2025 | marketbeat.com

Was Jim Cramer Right to Favor Another Stock Over Viking Therapeutics (VKTX)?

June 9, 2025 | msn.com

1 Stock Down 34% This Year to Buy and Hold

June 8, 2025 | fool.com

39,652 Shares in Viking Therapeutics, Inc. (NASDAQ:VKTX) Bought by RFG Advisory LLC

June 6, 2025 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Rating of "Buy" by Analysts

June 6, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYTM, VKTX, IDYA, and IRWD Company Descriptions

IDEAYA Biosciences NASDAQ:IDYA

$21.67 -0.19 (-0.87%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$21.67 0.00 (0.00%)

As of 06/20/2025 04:20 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Ironwood Pharmaceuticals NASDAQ:IRWD

$0.70 +0.00 (+0.40%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$0.72 +0.02 (+3.34%)

As of 06/20/2025 07:12 PM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Rhythm Pharmaceuticals NASDAQ:RYTM

$61.99 +0.51 (+0.83%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$61.28 -0.72 (-1.15%)

As of 06/20/2025 06:07 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Viking Therapeutics NASDAQ:VKTX

$26.01 -0.27 (-1.03%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$26.05 +0.04 (+0.16%)

As of 06/20/2025 07:59 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time